MONCYTE Health

MONCYTE Health is a Finnish biotech company focused on personalized treatment solutions for high cholesterol, a key risk factor for cardiovascular diseases. The company originated as a spinout from the University of Helsinki and has developed a patented technology that quantifies cellular processes affecting cholesterol metabolism. This innovative approach allows clinicians to predict and select the most effective cholesterol-lowering treatments for individual patients, moving beyond traditional trial-and-error methods. The core product is a diagnostic test that analyzes how cholesterol is transported and processed within human cells. This technology supports personalized drug therapies by revealing cellular mechanisms that influence the effectiveness of lipid-lowering medications. MONCYTE Health's solutions are designed for use in clinical settings, health centers, and research institutions, helping to achieve personal cholesterol targets and reduce cardiovascular risk. The company collaborates with major pharmaceutical firms, health clinics, and research centers, enhancing drug development and clinical decision-making. MONCYTE Health has secured significant investment and is involved in a Horizon Europe-funded project aimed at improving the diagnosis and treatment of familial hypercholesterolemia. Key leadership includes CEO Tamara Alagirova and CSO Simon Pfisterer, who bring extensive expertise in cardiovascular disease research.

• Employees 4
• Founded 2024